Clinical pharmacology of the angiotensin receptor antagonists

Journal of Clinical Hypertension

Volumn 3, Issue 1, 2001, Pages 45-49

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; DIOVAN HCTZ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DRUG METABOLITE; EPROSARTAN; FOSINOPRIL; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; LOSARTAN POTASSIUM; MYOCARDIS; PROTEIN; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN;

EID: 0034955454     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2001.00832.x     Document Type: Article

References (47)

1. Angiotensin-II receptors: New targets for antihypertensive therapy
2. Angiotensin converting enzyme inhibitors
3. Kinetics of angiotensin converting enzyme inhibitors in renal failure
4. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan, in mild-to-moderate hypertension
5. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan
6. Angiotensin II receptor binding inhibitors
7. BMS 180560, an insurmountable inhibitor of angiotensin-II stimulated responses: Comparison with losartan and EXP-3174
8. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntropic action
9. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor
10. Practical considerations of the pharmacology of angiotensin receptor blockers
11. Bioavailability of candesartan is unaffected by food in healthy volunteers administered candesartan cilexitil
12. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: Absolute bioavailability and effect of food
13. The metabolic fate of eprosartan in healthy volunteers
14. Pharmacokinetics of eprosartan in healthy subjects, patients with hypertension, and special populations
15. A dose proportionality study of eprosartan in healthy male volunteers
16. Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers
17. Lack of effect of food on the oral bioavailability of irbesartan in healthy male volunteers
18. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite, EXP3174 in humans
19. 14C] telmisartan in healthy volunteers
20. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man
21. Pharmacokinetics of intravenous and oral losartan in patients with heart failure
22. 14C-candesartan cilexitil in healthy volunteers
23. Valsartan: Preclinical and clinical profile of an antihypertensive angiotensin II antagonist
24. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174
25. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment
26. Protein binding of valsartan, a new angiotensin receptor antagonist
27. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes; role of cytochrome P4503A (4) in formation of the active metabolite EXP3174
28. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members
29. Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174
30. Pharmacokinetics of candesartan after single and multiple doses of candesartan cilexitil in young and elderly healthy volunteers
31. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency
32. The pharmacokinetics of candesartan cilexitil in patients with renal or hepatic impairment
33. The pharmacokinetics of losartan in renal insufficiency
34. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
35. Effect of renal function on the pharmacokinetics of valsartan
36. Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease
37. Pharmacokinetics and protein binding of eprosartan in healthy volunteers and in patients with varying degrees of renal impairment
38. Cardiorenal implications of angiotensin-receptor therapy
39. Efficacy and tolerability of losartan in hypertensive patients with renal impairment
40. Safety and efficacy of irbesartan in patients with hypertension and renal insufficiency
41. The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis
42. Evaluation of the losartan in hemodialysis (ELHE) study
43. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring